Patients with high-risk localized prostate cancer benefit from multimodality therapy of curative intent. Androgen-deprivation therapy (ADT) combined with radiation improves survival in this population. However, prior clinical trials of neoadjuvant ADT and surgery failed to consistently demonstrate a survival advantage. The development of novel, more potent hormonal agents presents an opportunity to revisit the potential for neoadjuvant therapy to improve long-term outcomes for patients with localized prostate cancer. We review recent advances in neoadjuvant approaches for prostate cancer and emerging clinical trials data supporting the use of neoadjuvant therapy prior to radical prostatectomy
Tolsotogo St., Saint Petersburg 197022, RussiaBackground. Prostate cancer (PCa) of a high and very h...
Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant horm...
Following new scientific insights, initial management for patients with high-risk nonmetastatic pros...
Patients with high-risk localized prostate cancer benefit from multimodality therapy of curative int...
ObjectivesEfforts to improve the clinical outcome for patients with localized high-risk prostate can...
Introduction: High-risk prostate cancer (HRPCa) represents a heterogeneous disease with potential ri...
Since the advent of reversible androgen deprivation, its use for a short period of time (usually 3 m...
Androgen deprivation therapy (ADT) has traditionally formed the mainstay of treatment for advanced/m...
Background: We aimed to identify the candidate prostate cancer patients suitable for neoadjuvant and...
Copyright © 2013 Stavros Sfoungaristos et al. This is an open access article distributed under the C...
Objective To describe the outcome, assessed as the level of prostate specific antigen (PSA), of a ma...
Objectives: To evaluate the long-term effects of 3-month neoadjuvant hormonal treatment in patients ...
Bing-Lei Ma,1,2,* Lin Yao,1,2,* Yu Fan,1,2 Yu Wang,1,2 Yi-Sen Meng,1,2 Qian Zhang,1,2 Zhi-Song He,1,...
Androgen-deprivation therapy (ADT) administered in neoadjuvant setting before radical prostatectomy ...
Since localized adenocarcinoma of the prostate is curable with radical prostatectomy, an important c...
Tolsotogo St., Saint Petersburg 197022, RussiaBackground. Prostate cancer (PCa) of a high and very h...
Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant horm...
Following new scientific insights, initial management for patients with high-risk nonmetastatic pros...
Patients with high-risk localized prostate cancer benefit from multimodality therapy of curative int...
ObjectivesEfforts to improve the clinical outcome for patients with localized high-risk prostate can...
Introduction: High-risk prostate cancer (HRPCa) represents a heterogeneous disease with potential ri...
Since the advent of reversible androgen deprivation, its use for a short period of time (usually 3 m...
Androgen deprivation therapy (ADT) has traditionally formed the mainstay of treatment for advanced/m...
Background: We aimed to identify the candidate prostate cancer patients suitable for neoadjuvant and...
Copyright © 2013 Stavros Sfoungaristos et al. This is an open access article distributed under the C...
Objective To describe the outcome, assessed as the level of prostate specific antigen (PSA), of a ma...
Objectives: To evaluate the long-term effects of 3-month neoadjuvant hormonal treatment in patients ...
Bing-Lei Ma,1,2,* Lin Yao,1,2,* Yu Fan,1,2 Yu Wang,1,2 Yi-Sen Meng,1,2 Qian Zhang,1,2 Zhi-Song He,1,...
Androgen-deprivation therapy (ADT) administered in neoadjuvant setting before radical prostatectomy ...
Since localized adenocarcinoma of the prostate is curable with radical prostatectomy, an important c...
Tolsotogo St., Saint Petersburg 197022, RussiaBackground. Prostate cancer (PCa) of a high and very h...
Several randomized controlled trials assessed the outcomes of patients treated with neoadjuvant horm...
Following new scientific insights, initial management for patients with high-risk nonmetastatic pros...